Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Afya Ltd Market Cap
From what 0 stock analysts predict, the share price for Afya Ltd (AFYA) might decrease by 76.37% in the next year. This is based on a 12-month average estimation for AFYA. Price targets go from $3.18987 to $4.43107. The majority of stock analysts believe AFYA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned AFYA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Afya Ltd to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AFYA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AFYA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andre Salles UBS | Neutral | $19.5 | Initiates | Aug 30, 2024 |
| Mauricio Cepeda Morgan Stanley | Equal-Weight | $19 | Maintains | Jun 21, 2024 |
| Javier Martinez Morgan Stanley | Equal-Weight | $23 | Downgrade | Jan 22, 2024 |
| Marcelo Santos JP Morgan | Neutral | $23 | Downgrade | Nov 27, 2023 |
| Javier Martinez Morgan Stanley | Overweight | $20.5 | Upgrade | Oct 13, 2023 |
| Mauricio Cepeda Credit Suisse | Outperform | $18 | Maintains | Nov 22, 2022 |
Credit Suisse | Outperform | Upgrade | Aug 23, 2022 | |
| Mauricio Cepeda Credit Suisse | Outperform | $19 | Upgrade | Apr 8, 2022 |
| Maria Tereza Azevedo UBS | Buy | $21 | Maintains | Mar 7, 2022 |
| Javier Martinez Morgan Stanley | Equal-Weight | $28.5 | Downgrade | Jul 21, 2021 |
UBS | Buy | Upgrade | Apr 15, 2021 | |
JP Morgan | Overweight | Upgrade | Feb 4, 2021 | |
JP Morgan | Neutral | Downgrade | Oct 19, 2020 | |
Goldman Sachs | Buy | Upgrade | Sep 28, 2020 | |
Credit Suisse | Neutral | Initiates | Aug 19, 2020 | |
UBS | Neutral | Downgrade | May 20, 2020 | |
JP Morgan | Overweight | $24.5 | Maintains | May 5, 2020 |
JP Morgan | Overweight | $33 | Maintains | Mar 9, 2020 |
UBS | Buy | $31 | Maintains | Jan 15, 2020 |
UBS | Buy | Initiates | Sep 19, 2019 |
When did it IPO
2019
Staff Count
0
Country
Brazil
Sector/Industry
Consumer Defensive/Education & Training Services
CEO
Market Cap
$1.48B
In 2023, AFYA generated $2.88B in revenue, which was a increase of 23.48% from the previous year. This can be seen as a signal that AFYA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Investors should monitor AFYA stock due to recent activity in the options market, indicating potential changes in stock performance.
Why It Matters - Increased options activity often signals anticipated volatility or significant price movement in AFYA stock, potentially affecting investment strategies and returns.
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Afya Limited (Nasdaq: AFYA) will host Afya Day on October 29, 2024, featuring presentations on company growth, strategy, and outlook in a hybrid format.
Why It Matters - Afya Limited's upcoming Afya Day will provide insights into its growth and strategy, potentially influencing investor confidence and stock performance based on management's outlook.
Mon, 23 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Afya Limited aims to provide 5 million free health consultations by 2030, aligning with Sustainable Development Goal 3 to promote health and well-being for all.
Why It Matters - Afya's commitment to providing 5 million free health consultations enhances its brand reputation and aligns with global health goals, potentially attracting investors focused on sustainability and social impact.
Fri, 06 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Afya Limited announced that Brazil's Ministry of Education has granted Universidade do Grande Rio Professor José de Souza Herdy the reestablishment of 10 medical seats.
Why It Matters - The reestablishment of medical seats at Unigranrio enhances Afya's educational capacity, potentially increasing revenue and market share in Brazil's medical education sector.
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Afya Limited's subsidiary received BRL500 million from the International Finance Corporation to support its expansion, marking IFC's first sustainability-linked loan.
Why It Matters - Afya Limited's receipt of BRL500 million from the IFC for expansion signals strong financial backing and growth potential, enhancing investor confidence in the company's future performance.
Thu, 29 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Afya reported 14% revenue growth in Q2 2024, aided by higher enrollment and improved margins. Positive developments include a Supreme Court ruling and new IFC financing, but long-term oversupply concerns exist.
Why It Matters - Afya's strong Q2 growth and favorable rulings enhance its outlook, but potential oversupply risks in Brazil's medical sector could impact future profitability.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
